A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Cytomegalovirus Infection After HSCT and PT-CY as GVHD Prophylaxis >> GVHD PROPHYLAXIS ERA
- Status
- COMPLETED
- Phase
- N/A
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients
- Status
- TERMINATED
- Phase
- PHASE4
Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)
- Status
- COMPLETED
- Phase
- PHASE4
A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)
- Status
- RECRUITING
- Phase
- PHASE2
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
- Status
- RECRUITING
- Phase
- PHASE2
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
The POUR (Postoperative Urinary Retention) Study
- Status
- COMPLETED
- Phase
- PHASE3